Company Profile
Anhui Nature Pharmaceutical Co., Ltd., positioned in Anqing, China, has been a stalwart in the chemical landscape since its establishment in 2005. The company is dedicated to the comprehensive process of research, development, and production, offering an extensive array of chemical products that encompass APIs, intermediates, and customized synthesis products. Anhui Nature Pharmaceutical's products find utility across diverse industries, including pharmaceuticals, fine chemicals, and food additives.
Situated in the 4th floor of the 6th building on the 8th Huangguan Road, Anqing Hi-Tech Development District, the company's plant is outfitted with state-of-the-art manufacturing equipment, including reactors, extractors, distillation towers, and related facilities. A team of seasoned chemists and technicians utilizes advanced laboratory equipment to uphold the product quality, exemplifying the company's commitment to quality control and continuous improvement, underscored by its ISO9001:2015 certification.
Anhui Nature Pharmaceutical's business model revolves around producing high-quality chemical products at competitive prices, earning recognition both domestically and internationally. Catering to pharmaceutical and chemical companies, alongside research institutions, the company's products are integral in various applications, including the production of APIs, intermediates, and custom synthesis products. The company's ability to customize products has fostered enduring relationships with customers and facilitated expansion into new markets.
In tandem with its research and development endeavors, Anhui Nature Pharmaceutical places a robust emphasis on sustainability. The company's environmental management system is meticulously crafted to minimize waste and pollution, prioritizing resource conservation. Upholding high standards of social responsibility and ethical conduct, Anhui Nature is unwavering in its dedication to contributing to the well-being of its employees, customers, and the broader community.
Anhui Nature Pharmaceutical Co., Ltd. emerges as a pioneering chemical entity in Anqing, China, characterized by its commitment to research, development, and production of diverse chemical products. With a focus on producing high-quality products at competitive prices, the company's dedication to sustainability and ethical practices solidifies its position as a leader in the chemical industry.
VIEW MORE VIEW LESS
Product List
| Product Name | Synonyms | CAS No. | Grate/Content | Operate |
|---|---|---|---|---|
Bosutinib Intermediate |
4-CHLORO-7-(3-CHLORO-PROPOXY)-6-METHOXY-QUINOLINE-3-CARBONITRILE;4-Chloro-7-(3-chloropropoxy)-3-cyano-6-methoxyquinoline;4-Chloro-7-(3-chloropropoxy)-3-cyano-6-methyloxyquinoline;4-Chloro-7-(3-chloropropoxy)-6-methoxy-3-quinolinecarbonitrile;7-(3-chloro-propoxy)-4-chloro-6-Methoxy-quinoline-3-carbonitrile;3-Quinolinecarbonitrile, 4-chloro-7-(3-chloropropoxy)-6-Methoxy- |
214470-68-5 | - / 99% | Inquiry |
Ibrutinib intermediate 330786-24-8 |
3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine;4-Amino-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidine;Ibrutinib N-2;Ibrutinib deacryloylpiperidine;1H-Pyrazolo[3,4-d]pyrimidin-4-amine, 3-(4-phenoxyphenyl)-;C17H13N5O;SCHEMBL200349;CHEMBL1242204;BCP08092;CS-M2418 |
330786-24-8 | Pharma Grade / 99% | Inquiry |
Ibrutinib intermediates 1022150-12-4 |
(R)-3-(4-Phenoxyphenyl)-1-(piperidin-3-yl)-1H-pyra |
1022150-12-4 | - / 99% | Inquiry |
Lumacaftor Intermediate |
Benzoic acid,3-(6-amino-3-methyl-2-pyridinyl)-,1,1-dimethylethyl ester;1,1-Dimethylethyl 3-(6-amino-3-methyl-2-pyridinyl)benzoate;tert-Butyl 3-(6-amino-3-methylpyridin-2-yl)benzoate |
1083057-14-0 | - / 99% | Inquiry |
Niraparib intermediates 1171197-20-8 |
tert-butyl (3s)-3-(4-aminophenyl)piperidine-1-carboxylate;(S)-tert-Butyl 3-(4-aminophenyl)piperidine-1-carboxylate;1-Piperidinecarboxylic acid, 3-(4-aminophenyl)-, 1,1-dimethylethyl ester, (3S)-;(S)-tert-butyl3-(4-aMinophenyl)piperidine-1-carboxylate;MFCD27921195;SCHEMBL1421908;tert-butyl (S)-3-(4-aminophenyl)piperidine-1-carboxylate;ZINC2553950;SB17771;AC-30616 |
1171197-20-8 | - / 99% | Inquiry |
Niraparib intermediates 138229-59-1 |
EOS-60871 |
138229-59-1 | - / 99% | Inquiry |
Ticagrelor intermediate 1006376-62-0 |
Cyclopropanecarboxamide,2-(3,4-difluorophenyl)-,(1R,2R)-;(1R,2R)-2-(3,4-Difluorophenyl)cyclopropanecarboxamide |
1006376-62-0 | - / 99% | Inquiry |
Ticagrelor intermediate 376608-71-8 |
Benzeneacetic acid,α-hydroxy-,(αR)-(1R,2S)-compd. with 2-(3,4-difluorophenyl)cyclopropanamine (1:1);Benzeneacetic acid,α-hydroxy-,(αR)-,compd. with (1R,2S)-2-(3,4-difluorophenyl)cyclopropanamine (1:1) |
376608-71-8 | - / 99% | Inquiry |
Velpatasvir intermediate 1378388-16-9 |
1,2-Pyrrolidinedicarboxylic acid,4-(methoxymethyl)-,1-(1,1-dimethylethyl) ester,(2S,4S)-;1-(1,1-Dimethylethyl) (2S,4S)-4-(methoxymethyl)-1,2-pyrrolidinedicarboxylate;(2S,4S)-1-(tert-Butoxycarbonyl)-4-(methoxymethyl)pyrrolidine-2-carboxylic acid;N-tert-Butoxycarbonyl-(4S)-4-Methoxymethyl-L-proline |
1378388-16-9 | - / 99% | Inquiry |